PERMANENT AWARD EVIDENCE

Request for Information - Oligonucleotides Onshoring

UK Health Security Agency · published 12 Jun 2026. This page preserves the identifiers and current held fields for one Contracts Finder release; it is not an invoice, performance assessment or complete contract history.

Contracts Finder release ID5a7709b3-44af-479f-b9f3-872c3c87bd24-901981
Open Contracting ID (OCID)ocds-b5fd17-52499bb7-2e61-4453-a285-d49e959c0e61
Buyer identifierGB-CFS-254798
Release typeplanning
PUBLISHED COMMERCIAL FIELDS

Values stay separate.

A tender estimate and an award value answer different questions. Neither is treated as cash paid.

Award value
Not disclosed
award field
Tender value
Not disclosed
tender field
Procurement method
Not stated
Category
goods
CPV
33696500
Laboratory reagents
Delivery
Not stated
E14 4PU
PUBLISHED DESCRIPTION

What the notice says

1. The purpose of this notice is to enhance the Authority's understanding of the marketplace and its options for sourcing for a potential future requirement. 2. The issuance of this request for information (RFI) does not constitute a sourcing exercise nor will the Authority pay any costs incurred in the preparation of a response to this RFI. 3. The UK Health Security Agency's (UKHSA) key objectives for this RFI are: a. understand the ability of the marketplace to fulfil its requirements; b. refine the scope of the requirements to best align to the marketplace; and c. inform the Authority's chosen route to market to best enable competition Description of Scope of Requirements: UKHSA sees access to oligonucleotide manufacturers as key to increasing the UK's biosecurity, preparedness and resilience for infectious diseases. Oligonucleotides are a ubiquitous reagent used widely at many stages for research, development and use of diagnostics and countermeasures for infectious disease. Synthetic oligonucleotides are used widely as essential components of molecular diagnostic assays, sequencing methods and for development of serological assays, as well as critical reagents in the research, development and manufacture of new vaccines and therapeutics. The market for oligonucleotide supply in the UK, when you include use outside of infectious disease-related applications, is significant. UKHSA would like to understand the breadth and depth of oligonucleotide manufacturing capability in the UK and globally. This includes what oligonucleotides are already being manufactured, and to what design, what dependencies or bottlenecks exist, how these are being applied to make a product, and the existing and potential scale of manufacturing capacity. Although UKHSA is interested in understanding international manufacturing capability, UKHSA is specifically interested in improving onshore manufacturing capability for oligonucleotides and would encourage respondents to reflect any future intentions in the UK. This information will be used to inform UKHSA's future approach to improve access to oligonucleotide products, and engagement with oligonucleotide manufacturers about UKHSA's requirements. Should you wish to respond to this Request for Information, please complete the response questionnaire which is found at the following link: https://atamis-1928.my.salesforce-sites.com/ProSpend__CS_ContractPage?SearchType=Projects&uid=a07Pz00001dZ2lOIAS&searchStr=request+for+inform

Tender statusplanning
STAGE-DATE LEDGER

Reported dates, without an invented lifecycle.

The current projection contains one award release, not a verified chain of planning, tender, award, contract and modification records. Dates are shown in source-field order and are not silently repaired.

  1. 01Notice publishedPublication timestamp on the held release12 Jun 2026
SUPPLIER EVIDENCE

Published names and exact identifiers

A company profile appears only when this release carries a usable company number. Name-only suppliers remain name-only.

No supplier is named in this projection. That does not prove the notice had no supplier in every source version.

SOURCE

Contracts Finder release

Published 12 Jun 2026 · held through the daily award projection · Open Government Licence v3.0.

Inspect the official JSON release ↗